MedTech Innovator

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

FibriCheck is a medically certified mobile application designed for the screening and monitoring of irregular heart rhythms, particularly atrial fibrillation. As a software-only solution, it allows users to measure their cardiac rhythm simply by placing their finger on their smartphone camera, making it accessible anytime and anywhere. The application automatically shares gathered information with medical professionals, facilitating quicker diagnoses and enabling tailored treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, leveraging everyday smartphones and wearables to accurately detect and monitor heart rhythm issues. This innovative approach aims to enhance cardiovascular care by providing users with effective tools to manage their heart health, ultimately improving efficiency and reducing costs associated with cardiovascular treatments.

DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.

SmartCardia SA is a Swiss company established in 2013, specializing in the design and development of cardiac monitoring devices and cloud-based artificial intelligence software. The company offers a comprehensive platform for real-time patient monitoring, integrating advanced wearable technology with machine learning capabilities. Their flagship product, powered by SmartNeuralNet, enables continuous tracking of vital health indicators such as heart rate, breathing rate, and skin conductance. This innovative approach aims to provide patients with chronic conditions actionable insights into their health, facilitating better management of their medical needs. By leveraging deep learning and remote monitoring, SmartCardia aims to enhance the quality of life for patients while ensuring that healthcare providers have access to critical data for informed decision-making.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Senseye, Inc. is a company based in Los Angeles, California, focused on developing smart contact lenses that non-invasively gather data from users. Founded in 2015, the company aims to infer human emotions, thoughts, and health states to support various applications in market research, disease diagnosis, and early detection of conditions such as strokes and heart attacks. By utilizing innovative measurements of ocular physiology, Senseye quantifies cognitive abilities, health metrics, and psychological well-being, including vital signs and cognitive load. The platform is designed to enhance clinicians' ability to provide personalized care, allowing them to establish baselines and monitor patient outcomes effectively. As the technology advances, Senseye intends to place greater emphasis on emotional responses and mental health diagnostics, offering new insights into cognitive and health parameters through standard camera equipment.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

JuneBrain, LLC is a Washington, D.C.-based company founded in 2017 that focuses on developing wearable and non-invasive imaging devices for multiple sclerosis patients. The technology allows patients to monitor their disease activity from home, facilitating earlier detection of MS attacks and enhancing the monitoring of treatment efficacy. By leveraging telemedicine, JuneBrain aims to optimize remote assessment for neurological diseases, thereby enabling clinicians to track patients outside traditional clinical settings. The company's long-term vision includes extending its device's applications to a broader range of neurodegenerative diseases, promoting more accessible and frequent monitoring of brain health.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Augment Health focuses on enhancing the management of bladder dysfunction, particularly for the 7 million patients affected by neurological diseases or injuries. The company is developing a noninvasive bladder monitor along with an AI algorithm that allows for home diagnostics, addressing the high rate of inconclusive results seen in clinical settings. By shifting bladder health monitoring out of the clinic, Augment Health's technology aims to prevent complications such as bladder muscle atrophy by notifying patients or caregivers when the catheter is full, thus promoting better bladder health management. This innovation targets a significant market valued at $12.3 billion, providing a practical solution to improve the quality of life for individuals facing bladder dysfunction.

LiveMetric is a medical device company focused on developing non-invasive sensing and deep data analytics solutions aimed at transforming the management of hypertension and cardiovascular diseases. The company has created a wearable, cuff-free device for blood pressure monitoring, which has received FDA clearance and is validated for accuracy against traditional arterial line measurements. This device offers continuous monitoring of vital signs, enabling healthcare providers to deliver AI-augmented care and treatment management. LiveMetric aims to empower patients, payors, and healthcare professionals with accurate, personalized data, facilitating better decision-making and improving the overall quality of care for individuals suffering from chronic cardiovascular conditions. By providing detailed daily activity mapping and real-time feedback, the company seeks to enhance the lives of millions worldwide affected by these health issues.

MindMics is an innovative wearable technology company focused on health monitoring through sound-based platforms integrated into earbuds and hearing aids. By capturing clinically meaningful biometrics in real-time, such as circadian rhythms, breathing rates, body temperature, and heartbeats, MindMics aims to enhance mental performance and overall well-being. The technology allows users to gain insights into their health, facilitating improved focus, satisfaction, and mindfulness. Through this approach, MindMics seeks to provide users with tailored products and experiences that promote mental peace and enhance daily living.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients at home. The device employs a closed-loop approach and machine learning algorithms to deliver personalized peripheral neuromodulation therapy. This innovative technology mediates a cardiovascular antiarrhythmic response, helping users to alleviate the burden of atrial fibrillation and address precursors such as premature atrial contractions. As a result, CardiaCare’s device offers users the potential for rapid clinical and symptomatic relief.

PyrAmes is a healthcare technology company focused on transforming the delivery of medical care through advanced sensor measurement. The company has developed a paper-thin, flexible device that enables non-invasive, continuous blood pressure monitoring. This ultra-low power device is designed to be accurate and wireless, making it suitable for patients across all age groups, from newborns to seniors. By providing a pain-free method for blood pressure monitoring, PyrAmes aims to enhance the quality of care offered by healthcare providers, particularly for vulnerable populations such as neonates.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

toSense, Inc. is a healthcare technology company based in San Diego, California, focused on developing innovative solutions for at-home monitoring of chronic illnesses, particularly for patients with conditions such as congestive heart failure and chronic obstructive pulmonary disease. The company's flagship product, the CoVa Monitoring System, is a wearable sensor designed to monitor various health parameters, including thoracic impedance, heart rate, and respiration rate. This device, worn as a necklace and secured with disposable electrodes, transmits vital signs to gateways that relay the data to a web-based system for clinical review. This technology allows healthcare providers to detect potential issues earlier than traditional monitoring methods, enabling timely intervention. Established in 2008 and formerly known as Perminova, Inc., toSense operates as a subsidiary of Baxter International Inc. and aims to address pressing medical challenges through its hardware and software solutions.

Respirix, Inc. is a United States-based company that specializes in developing advanced sensors for monitoring breath exhalation and cardiogenic oscillations. The company combines digital health software and hardware to deliver proprietary insights into the pulmonary vasculature in a non-invasive manner. Respirix's product pipeline focuses on both at-home monitoring and critical care applications, particularly targeting conditions such as heart failure and hemodynamics. Through its innovative technologies, Respirix aims to enhance patient care by providing accurate and real-time health monitoring solutions.

Sepsis Scout is a developer of a wearable patch aimed at predicting the onset of sepsis in high-risk patients in a home care setting. The device utilizes proprietary deep learning technology to enhance the accuracy of sepsis predictions compared to current standards of care. By enabling patients to monitor their health more effectively, Sepsis Scout's solution helps manage chronic illnesses and reduces the need for hospital visits, alleviating the fear and uncertainty associated with serious health conditions.

Bone Health Technologies, Inc. is a health technology company based in Redwood City, California, focused on developing innovative solutions for individuals with low bone density. Incorporated in 2018, the company has created OsteoBoost, a wearable medical device that provides a non-invasive treatment to prevent osteoporosis. This FDA-cleared device is designed to be worn on the lower back and utilizes whole-body vibration technology to deliver mechanical stimulation to the hips and spine, mimicking the effects of weight-bearing exercise. Clinical studies have demonstrated OsteoBoost's efficacy in significantly slowing down the loss of bone density and strength, particularly in postmenopausal women with osteopenia. By offering a convenient, pain-free alternative to pharmacological treatments, Bone Health Technologies aims to improve health outcomes for the approximately 64 million Americans at risk of osteoporotic fractures.

Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

Spire Health, established in 2013 and headquartered in San Francisco, specializes in developing health-tracking devices and remote patient monitoring solutions. The company's core product is a wearable device that senses physical movement, position, and breathing patterns, providing insights into daily activities and mental state through a mobile application. Spire Health focuses on chronic respiratory disease management, offering solutions for conditions such as COPD, congestive heart failure, asthma, and sleep disorders. Their mission is to empower patients and physicians with useful, actionable data by harnessing the power of algorithms and sensors, thereby improving health outcomes.

Nanowear, Inc. specializes in the development of textile-based nanosensor technology that facilitates wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, the company offers products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, which focuses on the monitoring and management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, which is transmitted to a web-based portal accessible by healthcare professionals via a mobile application. Nanowear's technology serves various sectors, including cardiac and neurological health, industrial safety, government, sports medicine, and performance diagnostics, providing accurate and continuous diagnostic data in a cost-effective and unobtrusive manner. The company also maintains a research and development facility in University Park, Pennsylvania.

Palmm is a medical device company that specializes in providing innovative solutions for excessive sweating, also known as hyperhidrosis. The company has developed a convenient at-home treatment that targets specific areas of the body, such as the hands, by applying a mild electrical current through wearable garments. This process effectively deactivates sweat glands for extended periods, offering a safe and non-invasive alternative for individuals seeking relief from profuse sweating. By addressing this common issue, Palmm aims to help customers regain confidence and improve their quality of life, allowing them to avoid the social discomfort often associated with excessive sweating.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.

TinyKicks is a technology company based in Irvine, California, founded in 2014 by France Helfer. The company specializes in developing a wireless smart sensor system that captures fetal movement to promote healthy pregnancy outcomes. Its flagship product, the TinyKicks eMotion fetal activity monitor, is a wearable device that detects and distinguishes between the baby's kicks and the mother's movements. This continuous monitoring system automatically uploads data to the user's smartphone, allowing pregnant women to track their baby's activity. By leveraging machine learning algorithms, TinyKicks can identify abnormal fetal movement patterns, alerting users to potential complications and thereby reducing the costs associated with pregnancy-related issues.

UnaliWear Inc., based in Austin, Texas, develops the Kanega watch, a multipurpose wearable designed for seniors to maintain independence and dignity. This discreet device offers features such as fall detection, medication reminders, and assistance for individuals who may wander, all through a voice-activated interface. The Kanega watch is equipped with various technologies, including cellular, Wi-Fi, GPS, and Bluetooth, allowing it to provide emergency support anywhere without the need for a smartphone. Its patented battery system ensures that the watch remains charged without requiring removal. Additionally, the device incorporates data-driven artificial intelligence to learn the user’s lifestyle, enabling it to offer predictive and preemptive assistance tailored to individual needs.

Vital Enterprises develops augmented reality software designed to enhance the performance of technicians engaged in complex manual tasks, particularly in manufacturing and field servicing environments. The company's innovative software, compatible with smart glasses, offers hands-free communication and an intuitive data display that supports skilled operators during assembly and maintenance activities. With features such as a comprehensive Augmented Reality Dashboard, technicians can access work instructions without the need for physical interaction, allowing them to check off and log each task step efficiently. Additionally, the software includes a see-what-I-see telepresence capability, which enables remote experts to provide immediate assistance, thereby improving operational efficiency and safety in sectors like healthcare.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.